Machine learning can increase the number of autonomous agents in biopharma bioprocess development and streamline the creation of therapies based on monoclonal antibodies, according to research published on BioRxiv. For example, scientists enhanced mAb development by melding a Bayesian algorithm, a digital twin of mAbs cultivation, with 24 parallel-running mini-bioreactor perfusion systems, expediting experiments to maximize cell volume in mAb production.